Cantor Fitzgerald currently has a “Overweight” rating and a $46.00 price objective on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share ...

On Wednesday, Cantor Fitzgerald maintained an Overweight rating on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), following the company’s recent webinar that focused on its launch strategy for ...

On Friday, Cantor Fitzgerald reiterated its Overweight rating on Compass Pathways plc (NASDAQ:CMPS), a life sciences company focused on developing psilocybin therapy for mental health conditions.

ECARX Holdings Inc. (NASDAQ:ECX – Free Report) – Analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of ECARX in a report issued on Wednesday, March 26th.

Cantor Fitzgerald Equity Opportunity Fd earns a Low Process Pillar rating. The main detractor from the rating is the fund's unimpressive long-term risk-adjusted performance. This can be seen in ...

Cantor Fitzgerald Large Cap Focused Fund earns an Above Average Process Pillar rating. The leading factor in the rating is the parent firm's five-year risk-adjusted success ratio of 81%.

Researchers at academic institutions nationwide say that U.S. science is being dismantled. Government Science Data: Vast ...

On Thursday, Cantor Fitzgerald reaffirmed its Overweight rating on shares of Summit Therapeutics plc (NASDAQ:SMMT), a biopharmaceutical company. According to InvestingPro data, the stock currently ...

EXCLUSIVE: Strange Darling‘s Willa Fitzgerald is starring opposite Russell Crowe and Harry Lawtey in Walden Media’s Cold War thriller Billion Dollar Spy, we can tell you first. Fitzgerald will ...